Trial Outcomes & Findings for Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis (NCT NCT03717896)
NCT ID: NCT03717896
Last Updated: 2026-06-23
Results Overview
Primary outcome of plasma bicarbonate levels over 24 hours (6, 12, 18, 24 hours) following enrollment
COMPLETED
PHASE2
102 participants
6, 12, 18, and 24 hours after enrollment
2026-06-23
Participant Flow
Participant milestones
| Measure |
Thiamine
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Overall Study
STARTED
|
53
|
49
|
|
Overall Study
COMPLETED
|
52
|
48
|
|
Overall Study
NOT COMPLETED
|
1
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Two randomized participants did not receive study drug and were excluded from the analysis population.
Baseline characteristics by cohort
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
Total
n=100 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Prior Insulin Use
No
|
14 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
13 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
27 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Age, Continuous
|
51 years
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
43 years
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
46 years
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Sex: Female, Male
Female
|
22 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
26 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
48 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Sex: Female, Male
Male
|
30 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
22 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
52 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
3 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
4 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Race (NIH/OMB)
Black or African American
|
20 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
11 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
31 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Race (NIH/OMB)
White
|
27 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
27 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
54 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Race (NIH/OMB)
More than one race
|
2 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
2 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
4 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
4 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
6 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Region of Enrollment
United States
|
52 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
48 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
100 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Diabetes Mellitus Type
Type 1 diabetes mellitus
|
37 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
36 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
73 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Diabetes Mellitus Type
Type 2 diabetes mellitus
|
15 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
12 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
27 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
DKA History
None
|
27 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
23 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
50 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
DKA History
Previous DKA
|
20 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
24 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
44 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
DKA History
Unknown
|
5 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
6 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Prior Insulin Use
Yes
|
38 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
35 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
73 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Insulin Pump Use
Yes
|
9 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
10 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
19 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Insulin Pump Use
No
|
43 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
38 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
81 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
No PMH
|
4 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
7 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
11 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
CAD
|
4 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
3 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
7 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Malignancy
|
7 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
3 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
10 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
CHF
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
2 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
COPD
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Dementia
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Diabetes
|
44 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
39 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
83 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Alcohol use disorder
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
HIV/AIDS
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
2 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Liver Disease
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Renal Disease
|
4 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
4 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
8 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Stroke/TIA
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Tobacco Use
|
7 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
3 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
10 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Selected Past Medical History (PMH)
Transplant
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
0 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Bicarbonate
|
9 mEq/L
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
8 mEq/L
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
8 mEq/L
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Anion Gap
|
24.9 mEq/L
STANDARD_DEVIATION 6.3 • n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
25.1 mEq/L
STANDARD_DEVIATION 6.7 • n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
25.0 mEq/L
STANDARD_DEVIATION 6.4 • n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Lactate
|
2.2 mmol/L
n=20 Participants
|
1.9 mmol/L
n=20 Participants
|
2.1 mmol/L
n=40 Participants
|
|
Insulin Drip at Enrollment
Yes
|
51 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
47 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
98 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Insulin Drip at Enrollment
No
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 Participants
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
2 Participants
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Baseline Sequential Organ Failure Assessment (SOFA) Score
|
1 scores on a scale
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 scores on a scale
n=20 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
1 scores on a scale
n=40 Participants • Two randomized participants did not receive study drug and were excluded from the analysis population.
|
|
Glucose
|
331 mg/dL
n=20 Participants
|
315 mg/dL
n=20 Participants
|
331 mg/dL
n=40 Participants
|
|
pH
|
7.19 pH
n=20 Participants
|
7.19 pH
n=20 Participants
|
7.19 pH
n=40 Participants
|
PRIMARY outcome
Timeframe: 6, 12, 18, and 24 hours after enrollmentPrimary outcome of plasma bicarbonate levels over 24 hours (6, 12, 18, 24 hours) following enrollment
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Plasma Bicarbonate Levels
6 hours
|
15.3 mEq/L
Standard Deviation 4.5
|
14.1 mEq/L
Standard Deviation 4.7
|
|
Plasma Bicarbonate Levels
12 hours
|
16.4 mEq/L
Standard Deviation 4.2
|
16.2 mEq/L
Standard Deviation 3.7
|
|
Plasma Bicarbonate Levels
18 hours
|
17.2 mEq/L
Standard Deviation 3.9
|
16.9 mEq/L
Standard Deviation 3.8
|
|
Plasma Bicarbonate Levels
24 hours
|
18.3 mEq/L
Standard Deviation 3.6
|
18.3 mEq/L
Standard Deviation 2.8
|
SECONDARY outcome
Timeframe: 6, 12, 18, and 24 hours after enrollmentSecondary outcome of lactate over 24 hours (6, 12, 18, 24 hours) following enrollment
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Lactate
24 hours
|
1.1 mmol/L
Interval 0.9 to 1.4
|
1.2 mmol/L
Interval 1.0 to 1.4
|
|
Lactate
6 hours
|
1.3 mmol/L
Interval 1.0 to 2.0
|
1.0 mmol/L
Interval 0.9 to 1.5
|
|
Lactate
12 hours
|
1.1 mmol/L
Interval 0.9 to 1.5
|
1.0 mmol/L
Interval 0.8 to 1.2
|
|
Lactate
18 hours
|
1.0 mmol/L
Interval 0.8 to 1.4
|
1.0 mmol/L
Interval 0.8 to 1.4
|
SECONDARY outcome
Timeframe: 6, 12, 18, and 24 hours after enrollmentSecondary outcome of anion gap over 24 hours (6, 12, 18, 24 hours) following enrollment
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Anion Gap
24 hours
|
12 mEq/L
Interval 10.0 to 16.0
|
12 mEq/L
Interval 10.0 to 13.0
|
|
Anion Gap
6 hours
|
16 mEq/L
Interval 13.0 to 18.0
|
15 mEq/L
Interval 12.0 to 18.0
|
|
Anion Gap
12 hours
|
13 mEq/L
Interval 11.0 to 16.0
|
12 mEq/L
Interval 11.0 to 14.0
|
|
Anion Gap
18 hours
|
12 mEq/L
Interval 10.0 to 14.0
|
13 mEq/L
Interval 10.0 to 14.0
|
SECONDARY outcome
Timeframe: 45 daysICU length of stay reflects the number of ICU admission days.
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
ICU Length of Stay
|
1.2 days
Interval 0.9 to 1.7
|
1.5 days
Interval 1.0 to 2.1
|
SECONDARY outcome
Timeframe: 45 daysHospital length of stay reflects how long it takes a diabetic ketoacidosis patient to recover to the point where he/she can be released from the hospital.
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Hospital Length of Stay
|
3.9 days
Interval 2.3 to 6.1
|
4.2 days
Interval 2.9 to 5.7
|
SECONDARY outcome
Timeframe: First 7 days after enrollmentThe duration of insulin therapy is calculated by examining the hospital clinical information systems for all records of IV insulin infusion beginning at the time of enrollment. The start and the stop time-stamps of medication infusion are used to calculate a duration of infusion.
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Duration of Insulin Therapy
|
18 hours
Interval 13.0 to 29.0
|
19 hours
Interval 14.0 to 29.0
|
SECONDARY outcome
Timeframe: 24 hoursThe SOFA score is a validated measure of organ dysfunction commonly used in critically ill patients, particularly those with sepsis. It evaluates the function of six organ systems-respiratory, cardiovascular, neurologic, hepatic, renal, and coagulation-based on routinely collected clinical and laboratory data. Each organ system is assigned a score from 0 (normal function) to 4 (most severe dysfunction), resulting in a total score ranging from 0 to 24. Higher SOFA scores indicate greater severity of organ failure and a higher risk of adverse outcomes. SOFA score in this study uses a modification in which the arterial oxygen saturation/fraction of inspired oxygen (SaO2 /FiO2) ratio is substituted for the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2 /FiO2 ratio).
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
SOFA Score (Sequential Organ Failure Assessement Score)
|
1 units on a scale
Interval 0.0 to 2.0
|
0 units on a scale
Interval 0.0 to 0.0
|
SECONDARY outcome
Timeframe: 24 hoursPopulation: Not all participants had analyzable data for each mitochondrial respiration parameter due to missing or incomplete measurements.
Oxygen consumption rate of circulating peripheral blood mononuclear cells measured using Seahorse. Basal respiration represents oxygen consumption under baseline conditions. ATP-linked respiration represents oxygen consumption coupled to ATP production, while proton leak represents oxygen consumption not linked to ATP synthesis. Maximal respiration represents the maximal capacity of the electron transport chain after uncoupling. Spare respiratory capacity represents the difference between maximal and basal respiration and indicates the ability to respond to increased energy demand. Non-mitochondrial respiration represents oxygen consumption independent of mitochondrial activity.
Outcome measures
| Measure |
Thiamine
n=52 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=48 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Oxygen Consumption by Circulating Mononuclear Cells
Non-mitochondrial
|
3.5 pmol O₂/min/10⁶ cells
Interval 2.3 to 4.8
|
4.1 pmol O₂/min/10⁶ cells
Interval 2.1 to 5.7
|
|
Oxygen Consumption by Circulating Mononuclear Cells
Basal
|
5.7 pmol O₂/min/10⁶ cells
Interval 4.1 to 9.2
|
6.2 pmol O₂/min/10⁶ cells
Interval 2.7 to 9.8
|
|
Oxygen Consumption by Circulating Mononuclear Cells
Max
|
22.3 pmol O₂/min/10⁶ cells
Interval 16.2 to 28.9
|
21.2 pmol O₂/min/10⁶ cells
Interval 9.1 to 36.9
|
|
Oxygen Consumption by Circulating Mononuclear Cells
ATP
|
5.8 pmol O₂/min/10⁶ cells
Interval 3.3 to 7.7
|
5.5 pmol O₂/min/10⁶ cells
Interval 2.9 to 8.7
|
|
Oxygen Consumption by Circulating Mononuclear Cells
Proton Leak
|
0.22 pmol O₂/min/10⁶ cells
Interval -0.09 to 1.02
|
0.07 pmol O₂/min/10⁶ cells
Interval -0.24 to 0.65
|
|
Oxygen Consumption by Circulating Mononuclear Cells
Spare
|
14.7 pmol O₂/min/10⁶ cells
Interval 8.8 to 23.5
|
14.6 pmol O₂/min/10⁶ cells
Interval 6.4 to 28.0
|
SECONDARY outcome
Timeframe: 24 hours and 72 hours (or at discharge if hostpial length of stay was less than 72 hours)Population: PDH activity measurements were available for 65 patients because of incomplete sample collection.
Secondary outcome of change in PDH specific activity over 72 hours or at discharge if patient's hospital length of stay was less than 72 hours. PDH activity and total PDH protein quantity were measured in isolated peripheral blood mononuclear cells (PBMCs) following selective disruption of the mitochondrial membrane, using a previously validated immunocapture and microplate-based enzymatic assay protocol. PDH-specific activity was calculated as the ratio of measured PDH enzymatic activity to the natural logarithm of PDH protein quantity (PDH activity / ln\[PDH quantity\]), providing a normalized metric that reflects the functional efficiency of the enzyme independent of its expression level. Higher values suggest higher enzymatic efficiency.
Outcome measures
| Measure |
Thiamine
n=33 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=32 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Pyruvate Dehydrogenase Activity
24 hours
|
1.42 mg of protein/ln(mini-units/min)
Interval 1.05 to 2.07
|
1.53 mg of protein/ln(mini-units/min)
Interval 1.15 to 2.03
|
|
Pyruvate Dehydrogenase Activity
72 hours (or at discharge if hostpial length of stay was less than 72 hours)
|
1.87 mg of protein/ln(mini-units/min)
Interval 1.25 to 2.98
|
1.53 mg of protein/ln(mini-units/min)
Interval 1.13 to 2.2
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 37 patients because of incomplete sample collection.
The Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall score is a measure of verbal learning and immediate memory. Participants are read a list of 12 words (from three semantic categories) and asked to recall as many words as possible across three consecutive learning trials. The Total Recall score is calculated as the sum of correctly recalled words across the three trials, yielding a possible range of 0 to 36, with higher scores indicating better verbal learning and memory performance. This score reflects both initial acquisition and short-term retention of verbal information and is commonly used to assess cognitive function in clinical research.
Outcome measures
| Measure |
Thiamine
n=17 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=20 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Hopkins Verbal Learning Test - Total Recall
|
22 scores on a scale
Interval 16.0 to 26.0
|
23 scores on a scale
Interval 18.0 to 26.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 34 patients because of incomplete sample collection.
The Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall score assesses retention of verbal information after a delay. Following completion of the three learning trials, participants are asked to recall the previously presented word list after a delay period (typically 20-25 minutes) without re-exposure to the words. The Delayed Recall score is calculated as the number of correctly recalled words, with a possible range of 0 to 12, where higher scores indicate better memory retention. This measure reflects the ability to consolidate and retrieve learned information over time and is commonly used to evaluate memory function in clinical and research settings.
Outcome measures
| Measure |
Thiamine
n=16 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=18 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Hopkins Verbal Learning Test - Delayed Recall
|
8 scores on a scale
Interval 6.0 to 10.0
|
7 scores on a scale
Interval 4.0 to 9.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 34 patients because of incomplete sample collection.
The Hopkins Verbal Learning Test-Revised (HVLT-R) Retention (%) score reflects the proportion of learned information that is retained over a delay. It is calculated as the ratio of the Delayed Recall score to the highest number of words recalled on any of the three immediate recall trials, multiplied by 100, yielding a percentage value. Scores typically range from 0% to 100%, with higher values indicating better retention of previously learned material. This measure provides an index of memory retention independent of initial learning performance.
Outcome measures
| Measure |
Thiamine
n=16 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=18 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Hopkins Verbal Learning Test - Retention
|
85 percentage
Interval 74.0 to 95.0
|
76 percentage
Interval 67.0 to 82.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 37 patients because of incomplete sample collection.
The Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index assesses recognition memory by evaluating the ability to distinguish previously learned words from novel distractors. During the recognition phase, participants are presented with a list of target words and distractor words and asked to identify those that were previously learned. The Recognition Discrimination Index is calculated as the number of true positives (correctly identified target words) minus the number of false positives (incorrectly identified distractor words), yielding a score typically ranging from -12 to 12. Higher scores indicate better recognition accuracy and discrimination ability, reflecting the integrity of memory retrieval processes.
Outcome measures
| Measure |
Thiamine
n=17 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=20 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Hopkins Verbal Learning Test - Recognition Discrimination Index
|
10 scores on a scale
Interval 8.0 to 11.0
|
11 scores on a scale
Interval 9.0 to 12.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 36 patients because of incomplete sample collection.
The Brief Visuospatial Memory Test (BVMT) assesses visuospatial learning and memory. Participants are shown six geometric designs for a brief period and asked to reproduce them from memory across three learning trials. Performance is scored based on the accuracy and placement of each design, with a total recall score ranging from 0 to 36, where higher scores indicate better visuospatial memory. A delayed recall trial is administered after a delay to assess retention of visual information. This measure evaluates the ability to encode, store, and retrieve visuospatial material.
Outcome measures
| Measure |
Thiamine
n=16 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=20 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Brief Visuospatial Memory Test
|
9 scores on a scale
Interval 6.0 to 13.0
|
12 scores on a scale
Interval 5.0 to 15.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 36 patients because of incomplete sample collection.
The Trail Making Test Part A (TMT-A) assesses visual attention, processing speed, and psychomotor function. Participants are instructed to connect numbered circles in sequential order as quickly as possible. The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance. There is no fixed maximum score, although testing is typically discontinued at a predefined time limit (commonly 300 seconds).
Outcome measures
| Measure |
Thiamine
n=16 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=20 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Trail Making Test - Test Part A
|
38 seconds
Interval 36.0 to 58.0
|
29 seconds
Interval 22.0 to 48.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 36 patients because of incomplete sample collection.
The Trail Making Test Part B (TMT-B) assesses executive function, including cognitive flexibility and set-shifting, in addition to processing speed. Participants are required to alternate between numbers and letters in sequence (e.g., 1-A-2-B) as quickly as possible. The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance. As with TMT-A, there is no fixed maximum score, and testing is typically discontinued at a predefined time limit (commonly 300 seconds).
Outcome measures
| Measure |
Thiamine
n=16 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=20 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Trail Making Test - Test Part B
|
96 seconds
Interval 68.0 to 142.0
|
84 seconds
Interval 54.0 to 162.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 37 patients because of incomplete sample collection.
The Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit Span subtest assesses attention, working memory, and concentration. Participants are asked to repeat sequences of numbers in forward order (Digit Span Forward), reverse order (Digit Span Backward), and ascending order (Digit Span Sequencing). Scores are based on the total number of correctly recalled sequences, with higher scores indicating better attention and working memory capacity. The total score ranges from 0 to 48.
Outcome measures
| Measure |
Thiamine
n=17 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=20 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: WAIS-IV Digit Span
|
24 scores on a scale
Interval 18.0 to 28.0
|
23 scores on a scale
Interval 20.0 to 28.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 36 patients because of incomplete sample collection.
The Animal Naming test is a measure of semantic verbal fluency and executive function. Participants are asked to name as many animals as possible within a fixed time period. The score is the total number of unique, correct animal names generated, with higher scores indicating better semantic memory retrieval and executive functioning. Scores range from 0 with no fixed upper limit.
Outcome measures
| Measure |
Thiamine
n=17 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=19 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Test of Verbal Fluency and Animal Naming
|
54 correct responses per minute
Interval 37.0 to 60.0
|
55 correct responses per minute
Interval 42.0 to 65.0
|
SECONDARY outcome
Timeframe: At hospital discharge, median of 4 daysPopulation: Data available for 36 patients because of incomplete sample collection.
The Test of Premorbid Functioning (TOPF) estimates an individual's baseline cognitive ability prior to illness or injury. Participants are asked to read aloud a list of irregularly spelled words, and performance is scored based on correct pronunciation. Scores are used to estimate premorbid intellectual functioning. Scores range from 0 to 70, with higher scores indicating higher estimated premorbid functioning. This measure helps contextualize current cognitive performance relative to expected baseline levels.
Outcome measures
| Measure |
Thiamine
n=17 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=19 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
Neurocognitive: Test of Premorbid Functioning
|
42 scores on a scale
Interval 25.0 to 56.0
|
42 scores on a scale
Interval 32.0 to 55.0
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 0, 24 hours, and 72 hours (or at discharge if hospital length of stay was less than 72 hours)Population: C-peptide measurements were available for 98 patients because of incomplete sample collection.
C-peptide levels measured at time of study drug administration, 24 hours, and at 72 hours (or at discharge if hospital length of stay was less than 72 hours).
Outcome measures
| Measure |
Thiamine
n=51 Participants
200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
200mg IV thiamine in 50mL 0.9% saline: Thiamine 200mg IV every 12 hours for 2 days
|
Placebo
n=47 Participants
100mL 0.9% saline twice daily for two days
Placebo: 50mL 0.9% saline
|
|---|---|---|
|
C-peptide Levels
Baseline
|
97.3 pmol/L
Interval 7.4 to 524.1
|
24.0 pmol/L
Interval 0.8 to 275.5
|
|
C-peptide Levels
24 hours
|
92.0 pmol/L
Interval 11.7 to 521.2
|
36.0 pmol/L
Interval 0.8 to 483.0
|
|
C-peptide Levels
72 hours (or at discharge if hospital length of stay was less than 72 hours)
|
167.5 pmol/L
Interval 2.9 to 883.7
|
39.8 pmol/L
Interval 0.8 to 570.5
|
Adverse Events
Thiamine
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place